ImmVirX receives $5.1 million R&D Tax Incentive
Melbourne, Australia 15 January 2025 – ImmVirX Pty Limited, a life sciences company focused on developing next-generation, receptor targeted oncolytic RNA immunotherapies to transform outcomes for patients with some of the most prevalent and challenging cancer types, has received a $5,079,136 Research and Development (R&D) tax refund as part of the Australian Federal Government’s R&D […]
First patients dosed in Phase 1b combination study in colorectal, gastric and ovarian cancer
Phase 1b trial will evaluate IVX037 and Innovent Bio’s anti-PD-1 inhibitor TYVYT® (sintilimab) in patients with late stage colorectal, gastric and ovarian cancer Trial open at 4 sites with further sites to open through Q4. Melbourne, Australia 28 October 2024 – ImmVirX Pty Limited, a clinical stage oncology company focused on developing next-generation, receptor targeted […]
ImmVirX reports on operations for FY24
Melbourne, Australia 1 October 2024 – ImmVirX Pty Limited, a life sciences company dedicated to pioneering the next generation of receptor-targeted immunotherapies for patients confronted with common yet formidable cancers, is pleased to provide a summary of its operations for the financial year ended 30 June 2024. The principal activity during the financial year was the […]
ImmVirX presents update on Phase 1a/b Clinical Study at Medical Oncology Group of Australia Annual Meeting
Strong recruitment with 14 patients to date – four sites open + more shortly. Well tolerated, no dose-limiting toxicities. Signs of anti-cancer monotherapy activity in 2 of first 10 late-stage colorectal cancer patients evaluable for response. Late-stage colorectal cancer patient with complete response in injected lesion and no new metastatic disease over one year since […]
ImmVirX appoints Dr. Oksana Zdanska as Medical Director
Melbourne, Australia, 16 April 2024 – ImmVirX Pty Limited, a life sciences company dedicated to pioneering the next generationof receptor-targeted immunotherapies for patients confronted with common yet formidable cancers, is pleased to announce the appointment of Dr Oksana Zdanska as Medical Director, commencing today. Dr. Zdanska is a highly regarded clinical leader with extensive experience […]
ImmVirX presents on its Phase 1a Clinical Study at Society for Immunotherapy of Cancer (SITC) Annual Meeting
Strong recruitment – commenced April 2023, 8 patients to date. Strong clinician interest across multiple sites. Intralesional administration well tolerated, no dose-limiting toxicities. Early signs of induction of potentially beneficial inflammatory cytokines/chemokines, such as CXCL10. Phase 1b combination with checkpoint inhibitor to open in early 2024. Melbourne, Australia 6 November 2023 – ImmVirX Pty Limited, a life […]
Cancer-fighting biotech ImmVirX secures $15m from OneVentures
You can read the full story here.
ImmVirX raising $25m led by renowned healthcare VC OneVentures
– Up to A$25 million to be raised in Series B Financing, funding ImmVirX through to 2026 – Leading healthcare venture capital investor OneVentures subscribing for A$15 million – Up to $10 million to be raised from existing shareholders and placement of any shortfall – Dr Jeannie Joughin, a Principal at OneVentures, to join ImmVirX […]
OneVentures backs cancer biotech ImmVirX in $25 million Series B
You can read the full story here.
ImmVirX enters the clinic with next generation oncolytic virus
First patient on trial in colorectal, gastric and ovarian cancer study (CP-IVX001) Melbourne, Australia 11 April 2023 – ImmVirX Pty Limited, a clinical stage oncology company focused on developing next-generation, receptor targeted oncolytic viral immunotherapies to transform outcomes for patients with some of the most prevalent and challenging cancer types, today announced that the first patient […]
